Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) FCF Margin (2019 - 2025)

Revolution Medicines has reported FCF Margin over the past 6 years, most recently at 2240.92% for Q4 2025.

  • Quarterly results put FCF Margin at 2240.92% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 108387.59% (changed N/A YoY), and the annual figure for FY2023 was 3094.14%, down 242931.0%.
  • FCF Margin for Q4 2025 was 2240.92% at Revolution Medicines, down from 1801.07% in the prior quarter.
  • Over the last five years, FCF Margin for RVMD hit a ceiling of 1801.07% in Q3 2025 and a floor of 17110.92% in Q4 2023.
  • Median FCF Margin over the past 4 years was 749.96% (2022), compared with a mean of 2169.3%.
  • Biggest five-year swings in FCF Margin: skyrocketed 182801bps in 2022 and later plummeted -1665527bps in 2023.
  • Revolution Medicines' FCF Margin stood at 427.57% in 2021, then fell by -7bps to 455.64% in 2022, then tumbled by -3655bps to 17110.92% in 2023, then skyrocketed by 87bps to 2240.92% in 2025.
  • The last three reported values for FCF Margin were 2240.92% (Q4 2025), 1801.07% (Q3 2025), and 17110.92% (Q4 2023) per Business Quant data.